Di-n-octyl phthalic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Di-n-octyl phthalic acid
• 英文别名: 3,4-dioctylphthalic acid
• 化学式: C₂₄H₃₈O₄
• 分子量: 390.6
• InChiKey: GENYBPRYOMJDAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  28
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'ATHÉROTROMBOSE
  申请人：KANDULA MAHESH

  公开号：WO2013024376A1

  公开（公告）日：2013-02-21

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.

  本公开提供公式I的化合物或其药用可接受的盐，以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以用于口服、经皮、经粘膜、糖浆、局部、延长释放、持续释放或注射的给药。这种组合物可用于治疗血管疾病或病况，如血栓性脑血管或心血管疾病或其相关并发症。
• WATER-STABLE COMPOUNDS, CATALYSTS AND CATALYSED REACTIONS
  申请人：Tulloch Arran Alexander Dickon

  公开号：US20100292449A1

  公开（公告）日：2010-11-18

  The invention provides a method of carrying out a Lewis-acid catalysed organic reaction in the presence of a Lewis acid catalyst comprising a metal-organic compound having the following formula: M(HO(CR 1 R 2 )z)a(O(CR 1 R 2 )z)bY—(CR 3 R 4 )χ-Y((CR 1 R 2 )zO)c((CR 1 R 2 )zOH)d.nR 5 OH (Formula I) in which: M is a metal atom, preferably titanium, zirconium, hafnium or iron (III) Y is selected from P and N, but Ss very preferably N; each R 1 , R 2 , R 3 and R 4 is independently selected from H, alkyl, aryl, substituted alkyl or substituted aryl, R 5 is hydrogen, an alkyl group, a hydroxy-functionalised alkyl group, a polyoxyalkylmoiety, R 6 O or R 7 COO where R 6 and R 7 may each represent H, alkyl, aryl or alkyl-aryl; d and a are each O or 1, b and c are each 1 or 2, b+c=the valency of M, a+b+c+d=4, each z is independently 1, 2, 3 or 4; x represents the least number of C atoms between the Y atoms and is 2 or 3 and n is a number in the range from 0 to 4. The metal-organic compound forms a stable hydrate in water which retains Lewis-acid catalytic properties.

  本发明提供了一种在存在Lewis酸催化剂的情况下进行Lewis酸催化的有机反应的方法，该Lewis酸催化剂包括具有以下公式的金属有机化合物：M(HO(CR1R2)z)a(O(CR1R2)z)bY—(CR3R4)χ-Y((CR1R2)zO)c((CR1R2)zOH)d.nR5OH（公式I），其中：M是金属原子，优选钛、锆、铪或铁(III)；Y选自P和N，但非常优选N；每个R1、R2、R3和R4独立地选自H、烷基、芳基、取代烷基或取代芳基；R5是氢、烷基、羟基功能化的烷基、聚氧烷基部分、R6O或R7COO，其中R6和R7各自可以代表H、烷基、芳基或烷基芳基；d和a各自是O或1，b和c各自是1或2，b+c等于M的价，a+b+c+d=4，每个z独立地是1、2、3或4；x代表Y原子之间最少的C原子数，是2或3，n是0到4之间的数。金属有机化合物在水中形成稳定的含水物，保留了Lewis酸催化性质。
• [EN] ADJUVANT COMPOUNDS<br/>[FR] COMPOSÉS ADJUVANTS
  申请人：UNIV LEIDEN

  公开号：WO2018197582A1

  公开（公告）日：2018-11-01

  Adjuvant compounds are described, as well as their conjugates comprising peptide antigens or other immunomodulatory moieties. Also described are methods of modulating immune responses in a subject in need thereof, as well as methods of treating cancer, viral or bacterial infections comprising administering the adjuvant compounds or the conjugates to a subject in need thereof.

  辅助化合物被描述，以及它们的共轭物，包括肽抗原或其他免疫调节部分。还描述了调节受试者免疫应答的方法，以及治疗癌症、病毒或细菌感染的方法，包括向需要的受试者施用辅助化合物或共轭物。
• METHODS OF TREATING A BLOOD VESSEL
  申请人：Kerber Charles W.

  公开号：US20090137981A1

  公开（公告）日：2009-05-28

  Described herein are methods for treating a blood vessel. In an embodiment, the method of treating a blood vessel comprises providing at least one manipulable tool in a blood vessel, depositing a non-solid polymerizable material into a deposition area of the vessel, wherein the polymerizable liquid hardens over time upon contact with blood in the blood vessel, and altering the shape of the polymerizable material while it hardens by manipulating the tool.

  描述了治疗血管的方法。在一个实施例中，治疗血管的方法包括在血管中提供至少一个可操作的工具，将非固体聚合材料沉积到血管的沉积区，其中聚合液体在与血管中的血液接触后随时间硬化，并通过操作工具在材料硬化时改变其形状。
• PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS
  申请人：Universiteit Leiden

  公开号：EP3095787A1

  公开（公告）日：2016-11-23

  The present invention relates to novel compounds which are highly selective inhibitors of diacylglycerol lipase α and β. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-α (alternative name: Sn1-specific diacylglycerol hydrolase a; DAGL-α) and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive ompounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity.

  这项发明涉及一种新型化合物，它们是高选择性的二酰甘油脂酶α和β的抑制剂。这些化合物适用于治疗或预防与增加2-花生四烯酰基甘油水平相关、伴随或由此引起的疾病。二酰甘油脂酶-α（另一名称：Sn1特异性二酰甘油水解酶a；DAGL-α）和-β是负责内源大麻素2-花生四烯酰基甘油的生物合成的酶。需要选择性和可逆的抑制剂来研究神经细胞中DAGLs的功能，以一种急性和暂时的方式。这些创新的化合物特别适用于治疗神经退行性疾病、炎症性疾病、药物滥用和受损的能量平衡，如肥胖症。